Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

Multifocal Primary Prostate Cancer Exhibits High Degree of Genomic Heterogeneity.

Løvf M, Zhao S, Axcrona U, Johannessen B, Bakken AC, Carm KT, Hoff AM, Myklebost O, Meza-Zepeda LA, Lie AK, Axcrona K, Lothe RA, Skotheim RI.

Eur Urol. 2018 Sep 1. pii: S0302-2838(18)30594-3. doi: 10.1016/j.eururo.2018.08.009. [Epub ahead of print]

PMID:
30181068
2.

Noninvasive Detection of ctDNA Reveals Intratumor Heterogeneity and Is Associated with Tumor Burden in Gastrointestinal Stromal Tumor.

Namløs HM, Boye K, Mishkin SJ, Barøy T, Lorenz S, Bjerkehagen B, Stratford EW, Munthe E, Kudlow BA, Myklebost O, Meza-Zepeda LA.

Mol Cancer Ther. 2018 Nov;17(11):2473-2480. doi: 10.1158/1535-7163.MCT-18-0174. Epub 2018 Aug 10.

PMID:
30097488
3.

Patterns of genomic evolution in advanced melanoma.

Birkeland E, Zhang S, Poduval D, Geisler J, Nakken S, Vodak D, Meza-Zepeda LA, Hovig E, Myklebost O, Knappskog S, Lønning PE.

Nat Commun. 2018 Jul 10;9(1):2665. doi: 10.1038/s41467-018-05063-1.

4.

Evaluation of commercial DNA and RNA extraction methods for high-throughput sequencing of FFPE samples.

Kresse SH, Namløs HM, Lorenz S, Berner JM, Myklebost O, Bjerkehagen B, Meza-Zepeda LA.

PLoS One. 2018 May 17;13(5):e0197456. doi: 10.1371/journal.pone.0197456. eCollection 2018.

5.

Sample-Index Misassignment Impacts Tumour Exome Sequencing.

Vodák D, Lorenz S, Nakken S, Aasheim LB, Holte H, Bai B, Myklebost O, Meza-Zepeda LA, Hovig E.

Sci Rep. 2018 Mar 28;8(1):5307. doi: 10.1038/s41598-018-23563-4.

6.

Preclinical Evaluation of Vemurafenib as Therapy for BRAFV600E Mutated Sarcomas.

Gouravan S, Meza-Zepeda LA, Myklebost O, Stratford EW, Munthe E.

Int J Mol Sci. 2018 Mar 23;19(4). pii: E969. doi: 10.3390/ijms19040969.

7.

Analysis of the miR-34 family functions in breast cancer reveals annotation error of miR-34b.

Engkvist ME, Stratford EW, Lorenz S, Meza-Zepeda LA, Myklebost O, Munthe E.

Sci Rep. 2017 Aug 28;7(1):9655. doi: 10.1038/s41598-017-10189-1.

8.

Multi-omics of 34 colorectal cancer cell lines - a resource for biomedical studies.

Berg KCG, Eide PW, Eilertsen IA, Johannessen B, Bruun J, Danielsen SA, Bjørnslett M, Meza-Zepeda LA, Eknæs M, Lind GE, Myklebost O, Skotheim RI, Sveen A, Lothe RA.

Mol Cancer. 2017 Jul 6;16(1):116. doi: 10.1186/s12943-017-0691-y.

9.

Multilevel genomics of colorectal cancers with microsatellite instability-clinical impact of JAK1 mutations and consensus molecular subtype 1.

Sveen A, Johannessen B, Tengs T, Danielsen SA, Eilertsen IA, Lind GE, Berg KCG, Leithe E, Meza-Zepeda LA, Domingo E, Myklebost O, Kerr D, Tomlinson I, Nesbakken A, Skotheim RI, Lothe RA.

Genome Med. 2017 May 24;9(1):46. doi: 10.1186/s13073-017-0434-0.

10.

High number of kinome-mutations in non-small cell lung cancer is associated with reduced immune response and poor relapse-free survival.

Helland Å, Brustugun OT, Nakken S, Halvorsen AR, Dønnem T, Bremnes R, Busund LT, Sun J, Lorenz S, Solberg SK, Jørgensen LH, Vodak D, Myklebost O, Hovig E, Meza-Zepeda LA.

Int J Cancer. 2017 Jul 1;141(1):184-190. doi: 10.1002/ijc.30726. Epub 2017 Apr 21.

11.

Monitoring multiple myeloma by quantification of recurrent mutations in serum.

Rustad EH, Coward E, Skytøen ER, Misund K, Holien T, Standal T, Børset M, Beisvag V, Myklebost O, Meza-Zepeda LA, Dai HY, Sundan A, Waage A.

Haematologica. 2017 Jul;102(7):1266-1272. doi: 10.3324/haematol.2016.160564. Epub 2017 Apr 6.

12.

Corrigendum: Sumoylation of Rap1 mediates the recruitment of TFIID to promote transcription of ribosomal protein genes.

Chymkowitch P, P AN, Aanes H, Koehler CJ, Thiede B, Lorenz S, Meza-Zepeda LA, Klungland A, Enserink JM.

Genome Res. 2017 Feb;27(2):334. doi: 10.1101/gr.218370.116. No abstract available.

13.

Use of liquid biopsies to monitor disease progression in a sarcoma patient: a case report.

Namløs HM, Zaikova O, Bjerkehagen B, Vodák D, Hovig E, Myklebost O, Boye K, Meza-Zepeda LA.

BMC Cancer. 2017 Jan 6;17(1):29. doi: 10.1186/s12885-016-2992-8.

14.

Genome Analysis of Osteosarcoma Progression Samples Identifies FGFR1 Overexpression as a Potential Treatment Target and CHM as a Candidate Tumor Suppressor Gene.

Barøy T, Chilamakuri CS, Lorenz S, Sun J, Bruland ØS, Myklebost O, Meza-Zepeda LA.

PLoS One. 2016 Sep 29;11(9):e0163859. doi: 10.1371/journal.pone.0163859. eCollection 2016.

15.

Preclinical evaluation of potential therapeutic targets in dedifferentiated liposarcoma.

Hanes R, Grad I, Lorenz S, Stratford EW, Munthe E, Reddy CC, Meza-Zepeda LA, Myklebost O.

Oncotarget. 2016 Aug 23;7(34):54583-54595. doi: 10.18632/oncotarget.10518.

16.

VOLIN and KJON-Two novel hyperdiploid myeloma cell lines.

Våtsveen TK, Børset M, Dikic A, Tian E, Micci F, Lid AH, Meza-Zepeda LA, Coward E, Waage A, Sundan A, Kuehl WM, Holien T.

Genes Chromosomes Cancer. 2016 Nov;55(11):890-901. doi: 10.1002/gcc.22388. Epub 2016 Jul 12.

PMID:
27311012
17.

TP53 Mutation Spectrum in Smokers and Never Smoking Lung Cancer Patients.

Halvorsen AR, Silwal-Pandit L, Meza-Zepeda LA, Vodak D, Vu P, Sagerup C, Hovig E, Myklebost O, Børresen-Dale AL, Brustugun OT, Helland Å.

Front Genet. 2016 May 11;7:85. doi: 10.3389/fgene.2016.00085. eCollection 2016.

18.

Unscrambling the genomic chaos of osteosarcoma reveals extensive transcript fusion, recurrent rearrangements and frequent novel TP53 aberrations.

Lorenz S, Barøy T, Sun J, Nome T, Vodák D, Bryne JC, Håkelien AM, Fernandez-Cuesta L, Möhlendick B, Rieder H, Szuhai K, Zaikova O, Ahlquist TC, Thomassen GO, Skotheim RI, Lothe RA, Tarpey PS, Campbell P, Flanagan A, Myklebost O, Meza-Zepeda LA.

Oncotarget. 2016 Feb 2;7(5):5273-88. doi: 10.18632/oncotarget.6567.

19.

Translocational renal cell carcinoma (t(6;11)(p21;q12) with transcription factor EB (TFEB) amplification and an integrated precision approach: a case report.

Lilleby W, Vlatkovic L, Meza-Zepeda LA, Revheim ME, Hovig E.

J Med Case Rep. 2015 Dec 9;9:281. doi: 10.1186/s13256-015-0749-7.

20.

Genomic landscape of liposarcoma.

Kanojia D, Nagata Y, Garg M, Lee DH, Sato A, Yoshida K, Sato Y, Sanada M, Mayakonda A, Bartenhagen C, Klein HU, Doan NB, Said JW, Mohith S, Gunasekar S, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Myklebost O, Yang H, Dugas M, Meza-Zepeda LA, Silberman AW, Forscher C, Tyner JW, Ogawa S, Koeffler HP.

Oncotarget. 2015 Dec 15;6(40):42429-44. doi: 10.18632/oncotarget.6464.

21.

Sumoylation of Rap1 mediates the recruitment of TFIID to promote transcription of ribosomal protein genes.

Chymkowitch P, Nguéa AP, Aanes H, Koehler CJ, Thiede B, Lorenz S, Meza-Zepeda LA, Klungland A, Enserink JM.

Genome Res. 2015 Jun;25(6):897-906. doi: 10.1101/gr.185793.114. Epub 2015 Mar 23. Erratum in: Genome Res. 2017 Feb;27(2):334.

22.

BRAF V600E mutation in early-stage multiple myeloma: good response to broad acting drugs and no relation to prognosis.

Rustad EH, Dai HY, Hov H, Coward E, Beisvag V, Myklebost O, Hovig E, Nakken S, Vodák D, Meza-Zepeda LA, Sandvik AK, Wader KF, Misund K, Sundan A, Aarset H, Waage A.

Blood Cancer J. 2015 Mar 20;5:e299. doi: 10.1038/bcj.2015.24.

23.

Metabolic reprogramming of metastatic breast cancer and melanoma by let-7a microRNA.

Serguienko A, Grad I, Wennerstrøm AB, Meza-Zepeda LA, Thiede B, Stratford EW, Myklebost O, Munthe E.

Oncotarget. 2015 Feb 10;6(4):2451-65.

24.

Identification of novel fusion genes in lung cancer using breakpoint assembly of transcriptome sequencing data.

Fernandez-Cuesta L, Sun R, Menon R, George J, Lorenz S, Meza-Zepeda LA, Peifer M, Plenker D, Heuckmann JM, Leenders F, Zander T, Dahmen I, Koker M, Schöttle J, Ullrich RT, Altmüller J, Becker C, Nürnberg P, Seidel H, Böhm D, Göke F, Ansén S, Russell PA, Wright GM, Wainer Z, Solomon B, Petersen I, Clement JH, Sänger J, Brustugun OT, Helland Å, Solberg S, Lund-Iversen M, Buettner R, Wolf J, Brambilla E, Vingron M, Perner S, Haas SA, Thomas RK.

Genome Biol. 2015 Jan 5;16:7. doi: 10.1186/s13059-014-0558-0.

25.

Performance comparison of four exome capture systems for deep sequencing.

Chilamakuri CS, Lorenz S, Madoui MA, Vodák D, Sun J, Hovig E, Myklebost O, Meza-Zepeda LA.

BMC Genomics. 2014 Jun 9;15:449. doi: 10.1186/1471-2164-15-449.

26.

The regulatory landscape of osteogenic differentiation.

Håkelien AM, Bryne JC, Harstad KG, Lorenz S, Paulsen J, Sun J, Mikkelsen TS, Myklebost O, Meza-Zepeda LA.

Stem Cells. 2014 Oct;32(10):2780-93. doi: 10.1002/stem.1759.

27.

Reexpression of LSAMP inhibits tumor growth in a preclinical osteosarcoma model.

Barøy T, Kresse SH, Skårn M, Stabell M, Castro R, Lauvrak S, Llombart-Bosch A, Myklebost O, Meza-Zepeda LA.

Mol Cancer. 2014 Apr 28;13:93. doi: 10.1186/1476-4598-13-93.

28.

Generation and characterization of an immortalized human mesenchymal stromal cell line.

Skårn M, Noordhuis P, Wang MY, Veuger M, Kresse SH, Egeland EV, Micci F, Namløs HM, Håkelien AM, Olafsrud SM, Lorenz S, Haraldsen G, Kvalheim G, Meza-Zepeda LA, Myklebost O.

Stem Cells Dev. 2014 Oct 1;23(19):2377-89. doi: 10.1089/scd.2013.0599. Epub 2014 Jun 30.

29.

Common fusion transcripts identified in colorectal cancer cell lines by high-throughput RNA sequencing.

Nome T, Thomassen GO, Bruun J, Ahlquist T, Bakken AC, Hoff AM, Rognum T, Nesbakken A, Lorenz S, Sun J, Barros-Silva JD, Lind GE, Myklebost O, Teixeira MR, Meza-Zepeda LA, Lothe RA, Skotheim RI.

Transl Oncol. 2013 Oct 1;6(5):546-53. eCollection 2013.

30.

Functional characterisation of osteosarcoma cell lines and identification of mRNAs and miRNAs associated with aggressive cancer phenotypes.

Lauvrak SU, Munthe E, Kresse SH, Stratford EW, Namløs HM, Meza-Zepeda LA, Myklebost O.

Br J Cancer. 2013 Oct 15;109(8):2228-36. doi: 10.1038/bjc.2013.549. Epub 2013 Sep 24.

31.

Deep Sequencing the MicroRNA Transcriptome in Colorectal Cancer.

Schee K, Lorenz S, Worren MM, Günther CC, Holden M, Hovig E, Fodstad O, Meza-Zepeda LA, Flatmark K.

PLoS One. 2013 Jun 18;8(6):e66165. doi: 10.1371/journal.pone.0066165. Print 2013.

32.

IR/IGF1R signaling as potential target for treatment of high-grade osteosarcoma.

Kuijjer ML, Peterse EF, van den Akker BE, Briaire-de Bruijn IH, Serra M, Meza-Zepeda LA, Myklebost O, Hassan AB, Hogendoorn PC, Cleton-Jansen AM.

BMC Cancer. 2013 May 20;13:245. doi: 10.1186/1471-2407-13-245.

33.

Rapid gene expression changes in peripheral blood lymphocytes upon practice of a comprehensive yoga program.

Qu S, Olafsrud SM, Meza-Zepeda LA, Saatcioglu F.

PLoS One. 2013 Apr 17;8(4):e61910. doi: 10.1371/journal.pone.0061910. Print 2013.

34.

Genome-wide map of quantified epigenetic changes during in vitro chondrogenic differentiation of primary human mesenchymal stem cells.

Herlofsen SR, Bryne JC, Høiby T, Wang L, Issner R, Zhang X, Coyne MJ, Boyle P, Gu H, Meza-Zepeda LA, Collas P, Mikkelsen TS, Brinchmann JE.

BMC Genomics. 2013 Feb 15;14:105. doi: 10.1186/1471-2164-14-105.

35.

Correlation of TP53 and MDM2 genotypes with response to therapy in sarcoma.

Ohnstad HO, Castro R, Sun J, Heintz KM, Vassilev LT, Bjerkehagen B, Kresse SH, Meza-Zepeda LA, Myklebost O.

Cancer. 2013 Mar 1;119(5):1013-22. doi: 10.1002/cncr.27837. Epub 2012 Nov 16.

36.

[Genome sequencing for personalized cancer treatment].

Skotheim RI, Meza-Zepeda LA, Hovig E, Lønning PE, Lothe RA, Myklebost O.

Tidsskr Nor Laegeforen. 2012 Nov 12;132(21):2406-8. doi: 10.4045/tidsskr.12.0784. Norwegian. No abstract available.

37.

Human ALKBH4 interacts with proteins associated with transcription.

Bjørnstad LG, Meza TJ, Otterlei M, Olafsrud SM, Meza-Zepeda LA, Falnes PØ.

PLoS One. 2012;7(11):e49045. doi: 10.1371/journal.pone.0049045. Epub 2012 Nov 8.

38.

Integrative analysis reveals relationships of genetic and epigenetic alterations in osteosarcoma.

Kresse SH, Rydbeck H, Skårn M, Namløs HM, Barragan-Polania AH, Cleton-Jansen AM, Serra M, Liestøl K, Hogendoorn PC, Hovig E, Myklebost O, Meza-Zepeda LA.

PLoS One. 2012;7(11):e48262. doi: 10.1371/journal.pone.0048262. Epub 2012 Nov 7.

39.

Modulation of the osteosarcoma expression phenotype by microRNAs.

Namløs HM, Meza-Zepeda LA, Barøy T, Østensen IH, Kresse SH, Kuijjer ML, Serra M, Bürger H, Cleton-Jansen AM, Myklebost O.

PLoS One. 2012;7(10):e48086. doi: 10.1371/journal.pone.0048086. Epub 2012 Oct 25.

40.

Epithelial-microbial crosstalk in polymeric Ig receptor deficient mice.

Reikvam DH, Derrien M, Islam R, Erofeev A, Grcic V, Sandvik A, Gaustad P, Meza-Zepeda LA, Jahnsen FL, Smidt H, Johansen FE.

Eur J Immunol. 2012 Nov;42(11):2959-70. doi: 10.1002/eji.201242543. Epub 2012 Sep 4.

41.

Cdc28 kinase activity regulates the basal transcription machinery at a subset of genes.

Chymkowitch P, Eldholm V, Lorenz S, Zimmermann C, Lindvall JM, Bjørås M, Meza-Zepeda LA, Enserink JM.

Proc Natl Acad Sci U S A. 2012 Jun 26;109(26):10450-5. doi: 10.1073/pnas.1200067109. Epub 2012 Jun 11.

42.

Identification of osteosarcoma driver genes by integrative analysis of copy number and gene expression data.

Kuijjer ML, Rydbeck H, Kresse SH, Buddingh EP, Lid AB, Roelofs H, Bürger H, Myklebost O, Hogendoorn PC, Meza-Zepeda LA, Cleton-Jansen AM.

Genes Chromosomes Cancer. 2012 Jul;51(7):696-706. doi: 10.1002/gcc.21956. Epub 2012 Mar 27.

PMID:
22454324
43.

Genome wide single cell analysis of chemotherapy resistant metastatic cells in a case of gastroesophageal adenocarcinoma.

Hjortland GO, Meza-Zepeda LA, Beiske K, Ree AH, Tveito S, Hoifodt H, Bohler PJ, Hole KH, Myklebost O, Fodstad O, Smeland S, Hovig E.

BMC Cancer. 2011 Oct 20;11:455. doi: 10.1186/1471-2407-11-455.

44.

mRNA expression profiles of primary high-grade central osteosarcoma are preserved in cell lines and xenografts.

Kuijjer ML, Namløs HM, Hauben EI, Machado I, Kresse SH, Serra M, Llombart-Bosch A, Hogendoorn PC, Meza-Zepeda LA, Myklebost O, Cleton-Jansen AM.

BMC Med Genomics. 2011 Sep 20;4:66. doi: 10.1186/1755-8794-4-66.

45.

Adipocyte differentiation of human bone marrow-derived stromal cells is modulated by microRNA-155, microRNA-221, and microRNA-222.

Skårn M, Namløs HM, Noordhuis P, Wang MY, Meza-Zepeda LA, Myklebost O.

Stem Cells Dev. 2012 Apr 10;21(6):873-83. doi: 10.1089/scd.2010.0503. Epub 2011 Aug 24.

PMID:
21756067
46.

Preclinical xenograft models of human sarcoma show nonrandom loss of aberrations.

Kresse SH, Meza-Zepeda LA, Machado I, Llombart-Bosch A, Myklebost O.

Cancer. 2012 Jan 15;118(2):558-70. doi: 10.1002/cncr.26276. Epub 2011 Jun 28.

47.

Multiple chromosomal monosomies are characteristic of giant cell ependymoma.

Dahlback HS, Brandal P, Krossnes BK, Fric R, Meling TR, Meza-Zepeda LA, Danielsen HE, Heim S.

Hum Pathol. 2011 Dec;42(12):2042-6. doi: 10.1016/j.humpath.2011.02.012. Epub 2011 Jun 17.

PMID:
21683982
48.

Depletion of murine intestinal microbiota: effects on gut mucosa and epithelial gene expression.

Reikvam DH, Erofeev A, Sandvik A, Grcic V, Jahnsen FL, Gaustad P, McCoy KD, Macpherson AJ, Meza-Zepeda LA, Johansen FE.

PLoS One. 2011 Mar 21;6(3):e17996. doi: 10.1371/journal.pone.0017996.

49.

DNA copy number changes in human malignant fibrous histiocytomas by array comparative genomic hybridisation.

Kresse SH, Ohnstad HO, Bjerkehagen B, Myklebost O, Meza-Zepeda LA.

PLoS One. 2010 Nov 9;5(11):e15378. doi: 10.1371/journal.pone.0015378.

50.

Evaluation of high-resolution microarray platforms for genomic profiling of bone tumours.

Kresse SH, Szuhai K, Barragan-Polania AH, Rydbeck H, Cleton-Jansen AM, Myklebost O, Meza-Zepeda LA.

BMC Res Notes. 2010 Aug 8;3:223. doi: 10.1186/1756-0500-3-223.

Supplemental Content

Loading ...
Support Center